COLUMBUS, Ohio – Internationally renowned cancer expert Dr. Julia White is the new director of breast radiation oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
"I'm very excited that Julia is now leading our breast radiation oncology program Ohio State," says Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and CEO of the James Cancer Hospital. "She is widely regarded as one of the leading breast radiation oncologists in the world. We are delighted to have such an esteemed cancer leader join the OSU faculty to help us reach our goal of a cancer-free world."
White, who also has been named vice-chair of the department of radiation oncology, serves as chair of the national Radiation Therapy Oncology Group (RTOG) Breast Cancer Group.
"As a breast cancer physician and radiation oncologist, my goal is to deliver radiation that is personalized to the specific cancer and the individual woman by using advanced radiation technology that can more precisely treat breast tumors – and as a result – improve the overall survival for women with breast cancer," says White, who also is a member of the National Cancer Institute's Breast Cancer Steering Committee. "We now know that breast cancer is not one disease, but that there are many different types of breast cancer and each woman has her own individual needs."
In addition, she has served as principal investigator on a number of important clinical studies that have helped establish the current standard of care in the treatment of breast cancer patients.
"Julia is considered the international authority in breast cancer as it pertains to radiation oncology," adds Dr. Arnab Chakravarti, chair and professor, department of radiation oncology and co-director, brain tumor program at OSUCCC – James. "Her clinical research has helped define the field of breast radiation oncology. She will also have an important role in expanding the clinical trials portfolio in breast cancer at the Ohio State."
White will see patients primarily at the Stefanie Spielman Comprehensive Breast Center, 1145 Olentangy River Rd. The center features a new radiation oncology wing that offers added convenience for patients by providing on-site access to radiation treatments in the same location where they can also receive digital mammography, diagnostic imaging and other breast health services.
"The clinical trials I oversee nationally are available at the Stefanie Spielman Comprehensive Breast Center and aim to answer how to use the newest radiation technology to most effectively cure breast cancer patients," says White. "My goal is to offer the most up-to-date breast cancer treatment to patients I care for today, and to design clinical trials to cure even more patients in the next generation."
White is the co-principal investigator on two major international trials (NSABP B-39/ RTOG 0413 and RTOG 1005) studying the best radiation approach in more than 6,000 women who have undergone a lumpectomy.
She holds memberships in almost a dozen professional and honorary societies, including American College of Radiology, American Society of Clinical Oncology and American Society of Therapeutic Radiology and Oncology, while also serving on several editorial boards including Journal of Clinical Oncology and International Journal of Radiation Oncology Biology Physics.
White earned her bachelor's degree in biology at Rosemont College in Rosemont, Penn., and her medical degree from Michigan State University's College of Human Medicine. Prior to joining Ohio State, White was a professor in the department of radiation oncology at the Medical College of Wisconsin in Milwaukee. She also served as department chair and medical director for the department of radiation oncology at Community Memorial Hospital in Menomonee Falls, Wis.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 210-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.
# # #
Contact: Eileen Scahill, Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu